Blood test for detecting tumor DNA in bladder and upper tract cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study conducted at AZ Sint-Lucas Gent to validate an internally developed ctDNA assay. Researchers compare tumor DNA mutations identified from tissue with mutations found in plasma DNA using a tumor-informed approach, mainly digital droplet PCR, with some sequencing as needed. The study also explores whether ctDNA presence or changes after treatment relate to patient outcomes over two years. No treatment is assigned by the study; participation involves blood draws and analysis during routine clinical care. The goal is to determine the assay’s accuracy and potential role in monitoring disease burden and response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Histologically confirmed muscle-invasive bladder cancer or suspected muscle-invasive upper tract urothelial carcinoma, stage T2 or higher.
* Availability of tumor tissue from transurethral resection of bladder tumor, ureteroscopic biopsy, biopsy of a metastatic lesion, or nephroureterectomy for DNA extraction.
* Written informed consent provided.

Exclusion Criteria:

\- Concurrent active malignancy diagnosed within the past 5 years.

Where it's running

• AZ Sint-Lucas Gent
  Ghent, East Flanders, Belgium Recruiting

Study contacts

• Study coordinator: Jeroen Van Besien, MD
• Email: Secretariaat.Urologie@AZSTLUCAS.BE
• Phone: 003292246650

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Non-invasive urine test to screen for urothelial cancer in adults with blood in urine

  A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.

  Recruiting Henan Provincial People's Hospital · Zhengzhou, Henan · NCT07614594

• Comparing CT and MRI with VI-RADS for Bladder Cancer Staging

  This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.

  Recruiting Oslo University Hospital · Oslo · NCT07602010

• Assessing safety and efficacy of new treatments for advanced solid tumors

  This study is testing two new treatments for patients with advanced solid tumors to see if they are safe and effective.

  Recruiting at 10 sites Phase 1/2 Lumara Bio Oncologics GmbH · Melbourne and 9 other locations · NCT05706129

• Perioperative systemic therapies in muscle-invasive bladder cancer (GUARDIANS)

  This registry will see how real-world perioperative treatments for muscle-invasive bladder cancer work in adults, including regimens like Enfortumab Vedotin with Pembrolizumab and cisplatin-based plans.

  Recruiting LMU Klinikum · Munich · NCT07855926

• Trop2-targeted NIR-II probe to identify bladder cancer in ex vivo samples

  A phase 2 study tests whether a Trop2-targeted NIR-II fluorescent probe can highlight bladder cancer lesions on ex vivo bladder tissue from patients undergoing radical cystectomy.

  Recruiting Phase 2 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07848854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.